info icon

This is a non-core endpoint: only basic statistics are computed.

Disorders of glycoprotein metabolism

E4_GLYCOPROT

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 E77
  • Cause of death: ICD-10 E77

2 out of 7 registries used, show all original rules.

42

4. Check minimum number of events

None

42

5. Include endpoints

42

6. Filter based on genotype QC (FinnGen only)

42

Control definitions (FinnGen only)

Control exclude
E4_METABOLIA

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E70-E90
Name in latin
Perturbationes metabolismi glycoproteinorum

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 490 243 246
Only index persons 390 191 199
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 39.76 40.27 39.07
Only index persons 38.47 38.07 38.86

-FinnGen-

Key figures

All Female Male
Number of individuals 42 23 19
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 52.01 52.52 51.39

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

No data available

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
10
9
14.08
6.17
3.0
2.1
—
—
—
0
0
21
75
4.60
5.58
6.7
2.5
—
—
—
0
0
8
11
8.67
4.07
1.0
1.4
—
—
—
0
0
8
12
7.93
3.87
1.3
1.2
—
—
—
0
0
22
101
3.47
3.80
2.0
1.8
95.3
102.2
pmol/l
0.22
12
50
29
167
3.38
3.33
8.1
5.0
51.9
53.5
%
0.40
29
156
19
86
3.21
3.26
4.1
2.1
—
—
—
0
0
29
172
3.22
3.07
8.2
5.0
33.5
31.7
%
0.45
29
158
22
112
3.02
3.05
4.5
2.3
—
—
—
0
0
27
160
2.92
2.76
11.4
7.7
0.0
0.0
e9/l
0.00
27
126
20
103
2.80
2.63
11.1
4.7
1.4
1.2
inr
—
6
25
5
7
7.90
2.62
4.2
1.1
120.8
228.0
ug/l
—
5
7
13
54
3.04
2.49
1.5
1.5
25.4
23.6
nmol/l
0.10
13
47
12
48
3.10
2.44
2.4
1.8
433.7
475.0
pmol/l
0.37
12
41
22
123
2.66
2.43
7.7
4.8
36.1
36.2
g/l
0.02
22
115
10
37
3.23
2.29
2.4
1.5
—
—
—
0
0
28
182
2.62
2.20
8.1
5.1
2.2
2.6
e9/l
0.23
28
160
14
67
2.63
2.05
3.2
3.2
1.0
1.0
kg/l
—
8
12
20
114
2.44
2.04
4.0
2.6
—
—
—
0
0
5
12
4.57
1.88
7.8
2.6
1.3
1.0
%
—
5
12
0
48
0.00
1.84
0.0
1.4
—
—
—
0
0
25
165
2.27
1.76
8.1
5.1
3.6
2.9
%
0.62
25
153
14
72
2.42
1.74
7.1
4.6
—
—
—
0
0
25
166
2.25
1.72
8.2
5.3
8.4
8.3
%
0.06
25
156
24
158
2.21
1.67
8.4
5.1
0.9
0.7
%
1.73
24
144
5
14
3.90
1.66
8.6
7.4
25.4
26.5
mmol/l
—
5
14
5
15
3.63
1.57
8.0
4.7
—
—
—
0
0
7
29
2.69
1.46
4.4
4.1
—
—
—
0
0
15
86
2.16
1.43
3.3
2.8
—
—
—
0
0
6
24
2.74
1.35
2.5
2.0
—
—
—
0
0
13
76
2.03
1.15
1.8
2.5
—
—
—
0
0
24
174
1.89
1.14
8.0
5.2
0.6
0.5
e9/l
0.52
24
149
24
174
1.89
1.14
8.1
5.2
0.0
0.0
e9/l
1.07
24
150
12
69
2.03
1.11
7.2
3.3
—
—
—
0
0
9
50
2.01
1.05
2.7
2.1
167.4
64.4
ug/g
—
9
44
0
24
0.00
0.82
0.0
1.3
—
—
—
0
0
9
135
0.58
0.78
3.9
1.8
—
—
—
0
0
28
228
1.68
0.77
4.3
3.1
—
—
—
0
0
7
41
1.85
0.74
1.9
1.7
—
—
—
0
0
6
100
0.53
0.74
1.5
1.6
1.9
1.2
mmol/l
—
6
84
13
88
1.69
0.71
4.3
1.9
630.9
127.0
u/l
0.48
13
79
5
27
1.96
0.71
2.2
5.5
5.0
5.3
kpa
—
5
27
17
126
1.59
0.66
8.8
4.9
—
—
—
0
0
22
175
1.54
0.62
6.5
5.4
21.2
13.6
umol/l
0.33
22
165
6
37
1.72
0.58
1.3
1.2
—
—
—
0
0
6
37
1.72
0.58
3.5
1.4
—
—
—
0
0
17
131
1.50
0.54
5.2
2.3
106.2
88.8
ug/l
0.18
17
120
7
47
1.59
0.51
2.4
1.4
1236.6
1293.2
nmol/l
—
7
34
7
50
1.48
0.48
3.4
1.6
—
—
—
0
0
5
33
1.58
0.43
5.4
5.4
—
—
—
0
0
0
15
0.00
0.42
0.0
1.4
—
1.2
—
0
15
25
216
1.39
0.40
9.8
8.8
3.6
3.7
e9/l
0.14
25
186
13
101
1.42
0.37
2.2
2.2
—
—
—
0
0
12
92
1.43
0.37
8.3
4.8
14.0
1.8
ug/l
0.48
12
76
6
43
1.46
0.37
1.8
1.4
—
—
—
0
0
5
39
1.32
0.24
1.2
1.5
—
—
—
0
0
12
99
1.30
0.23
1.3
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
0.2
—
0
14
9
105
0.82
0.15
5.6
2.9
2.3
2.4
mmol/l
—
9
94
27
255
1.16
0.11
7.7
3.7
16.7
9.8
mm/h
1.34
27
232
6
55
1.11
0.09
3.7
1.6
—
—
—
0
0
34
347
0.89
0.08
16.1
11.3
27.1
40.9
%
2.46
20
272
8
75
1.08
0.08
2.1
3.1
—
—
—
0
0
32
326
0.92
0.01
6.1
4.3
1.8
1.9
mu/l
0.21
32
297
24
239
1.01
0.00
3.2
3.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
17.8
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
5
50
1.00
0.00
1.2
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
9
96
0.92
0.00
6.7
5.8
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint E4_GLYCOPROT and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
E4_GLYCOPROT 5.737 [3.32, 9.92] < 0.001
Birth year 0.985 [0.98, 0.99] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 195 males with E4_GLYCOPROT died.

Mortality risk

Mortality risk for people of age

years, who have E4_GLYCOPROT.

N-year risk Females Males
1 No data 0.985%
5 No data 5.653%
10 No data 14.629%
15 No data 26.381%
20 No data 40.026%

Relationships between endpoints

Index endpoint: E4_GLYCOPROT – Disorders of glycoprotein metabolism

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data